Eficacia y seguridad de las Vacunas NVXCoV2373 de Novavax contra el COVID-19

Cómo citar

Morón Duarte, L. S., Yomayusa, N. ., & Low Padilla, E. (2022). Eficacia y seguridad de las Vacunas NVXCoV2373 de Novavax contra el COVID-19. Revista Médica Sanitas, 23(3-4). https://doi.org/10.26852/01234250.62





European Medicines Agency. EMA starts rolling review of Novavax’s COVID-19 vaccine (NVX-CoV2373) [Internet]. 2021. Available from: https://www.ema.europa.eu/en/news/ema-starts-rolling-reviewnovavaxs-covid-19-vaccine-nvx-cov2373

Government of Canada. Drug and vaccine authorizations for COVID-19: List of applications received [Internet]. Available from: https://www.canada.ca/en/health-canada/services/drugs-healthproducts/covid19-industry/drugs-vaccines-treatments/authorization/applications.html

Novavax. Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization [Internet]. 2021. Available from: https://ir.novavax.com/news-releases/newsrelease-details/novavax-announces-start-rolling-review-multiple-regulatory

Novavax. Novavax COVID-19 Vaccine Demonstrates 89.3 % Efficacy in UK Phase 3 Trial. 2021;(August 2020):2–4. Available from: https://ir.novavax.com/node/15506/pdf

Copyright © 2020 MU and EPIA rights reserved. GRADEpro software [Internet]. 2020. Available from:


Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1–2 Trial of a SARS-CoV-2

Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med [Internet]. 2020 Sep 2;383(24):2320–32. Available from: https://doi.org/10.1056/NEJMoa2026920


Los datos de descargas todavía no están disponibles.